Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07112690 · ClinicalTrials.gov registry record · NA
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
A NA study of Stage I Anal Cancer AJCC v8 and Localized Anal Carcinoma, sponsored by Emory University.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT07112690 is a NA study of Stage I Anal Cancer AJCC v8 and Localized Anal Carcinoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 5 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT07112690, a NA study of Stage I Anal Cancer AJCC v8 and Localized Anal Carcinoma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized). Treatment for anal or perianal skin cancer includes giving chemotherapy and radiation therapy (CRT) at the same time. CRT is frequently associated with several side effects, including radiation-induced pain. Despite advances in radiation therapy delivery, patients may still experience side effects which can lead to treatment breaks or treatment discontinuation. Ganglion impar neurolysis is a type of nerve block procedure in which medicine is injected directly into or around a nerve to block pain. The location of the procedure is near the tail bone and the medicine numbs the nerves that are in charge of sensation in the skin by the buttocks and genitalia. This may improve radiation-induced pain in patients receiving CRT for localized anal or perianal skin cancer.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Electronic Health Record Review
- PROCEDURE Fluoroscopy
- PROCEDURE Ganglion Impar Neurolysis
Study Locations (2)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Grady Health System - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2027-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07112690
The ClinicalTrials.gov registry entry for NCT07112690 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Stage I Anal Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT07112690 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT07112690 about?
NCT07112690 is a clinical study titled "Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment". This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized). Treatment for anal or perianal skin cancer includes giving chemotherapy and radiatio...
What is the current status of trial NCT07112690?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2025-11-10. Estimated completion is 2027-09-30.
What conditions does trial NCT07112690 study?
This clinical trial studies the following conditions: Stage I Anal Cancer AJCC v8, Localized Anal Carcinoma, Localized Anal Margin Carcinoma, Stage 0 Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8.
What interventions are being tested in trial NCT07112690?
The interventions under investigation include: Questionnaire Administration (OTHER), Electronic Health Record Review (OTHER), Fluoroscopy (PROCEDURE), Ganglion Impar Neurolysis (PROCEDURE).
Who is sponsoring clinical trial NCT07112690?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07112690 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage I Anal Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.